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A current major obstacle is that no reliable screening markers exist to detect pregnancies at risk for preeclampsia. Quantitative
proteomic analysis employing isobaric labelling (iTRAQ) has been suggested to be suitable for the detection of potential plasma
biomarkers,afeaturewerecentlyveriﬁedinanalysisofpregnancieswithDownsyndromefoetuses.Wehavenowexaminedwhether
this approach could yield biomarkers to screen pregnancies at risk for preeclampsia. In our study, we used maternal plasma
samples obtained at 12 weeks of gestation, six from women who subsequently developed preeclampsia and six with uncomplicated
deliveries.Inouranalysis,weobservedelevationsin10proteinsoutof64proteinsinthepreeclampsiastudygroupwhencompared
to the healthy control group. These proteins included clusterin, ﬁbrinogen, ﬁbronectin, and angiotensinogen, increased levels
of which are known to be associated with preeclampsia. An elevation in the immune-modulatory molecule, galectin 3 binding
protein, was also noted. Our pilot study, therefore, indicates that quantitative proteomic iTRAQ analysis could be a useful tool for
the detection of new preeclampsia screening markers.
1.Introduction
Preeclampsiaisamajorhealthconcern,asitisaleadingcause
of fetal and maternal mortality and morbidity, worldwide
[1]. A major clinical deﬁcit is that no reliable screening
markers exist to detect at-risk pregnancies, thereby oﬀering
noopportunityforinterveningtherapiespriortotheonsetof
symptoms [2,3]. This is especiallyrelevant forsevere casesof
early onset forms of the disorder, resulting in the delivery of
prematurebabies,whoarefrequentlyaﬀectedbyintrauterine
growth retardation.
It is widely accepted that the underlying aetiology of this
enigmatic disorder, characterised by sudden hypertension in
previously normotensive pregnant women, involves the pla-
centa.Inthiscontext,theplacentaeofearlyonsetpreeclamp-
sia are usually characterised by abnormalities in trophoblast
diﬀerentiation, lack of modiﬁcation of the maternal spiral
arteries, and ill-deﬁned villous structure [4].
Recent studies have indicated that the clinical symptoms,
such as hypertension and proteinuria, are largely brought
about by alterations in the levels of angiogenic factors
produced by the placenta such as placental growth factor
(PIGF), vascular endothelial growth factor (VEGF), soluble
Flt-1, and endoglin [5, 6] Although alterations in the levels
of these cytokines do precede the onset of clinical symptoms,
it is not clear how eﬀective they will be as screening markers,
as these changes occur relatively late in gestation.
Ac o n s i d e r a b l ee ﬀort in prenatal medicine is being de-
votedtothedevelopmentofeﬃcaciousﬁrsttrimesterscreen-
ing tools, to detect pregnancies at risk for fetal aneuploidies,
but also pregnancy-related disorders such as preeclampsia,
as this would permit suﬃcient time for intervention. In this2 Journal of Biomedicine and Biotechnology
regard, quantitative changes at 11–14 weeks of pregnancy in
proteins such as ADAM-12 [7], PP-13 (placental protein13)
[8,9],andpregnancy-associatedplasmaprotein-A(PAPP-A)
in combination with Doppler ultrasound, have been shown
to posses some predictive value in detecting cases at risk for
preeclampsia [10].
Since the aetiological cascade leading to the develop-
ment of manifest preeclampsia is multifactorial, it is very
unlikely that a single molecule (or small group of analytes)
will possess suﬃcient sensitivity and speciﬁcity. Hence, new
strategies will need to be explored in order to increase the
pool of biomarker candidates.
One such route is by proteomic analysis of the maternal
plasma proteome. The underling rationale for such inves-
tigations is that as the placenta is in direct contact with
the maternal circulation, proteins released by it should be
detectable in maternal plasma. Since preeclampsia is asso-
ciated with structural placental anomalies, the underlying
alterations in protein expression should be reﬂected in
plasma proteome. Consequently, this serves as a promising
route for the detection of biomarkers indicative of abnormal
placentation [11].
Consequently, a recent study carried out under this
premise[12]hasshownthatalterationsinproteinexpression
are evident maternal serum or plasma of aﬀected pregnan-
cies. Unfortunately the validity of these studies is limited,
as they were performed on samples obtained from cases
with manifest symptoms and, furthermore, did not employ
state-of-the-art quantitative approaches permitting precise
assessment of the extent of up- or downregulation of the
newly discovered markers.
A further limitation in these studies is the extremely
complex nature of the plasma/serum proteome, whereby
low-abundance proteins are masked by the preponderance
of a small number of highly abundant plasma proteins. In
addition, the high dynamic range of the plasma proteome
precludes the use of conventional proteomic strategies
employing gel electrophoresis, even when making use of
ﬂuorescent labeling, for example, DIGE (diﬀerence gel
electrophoresis).Hence,theidentiﬁcationofnewbiomarkers
in plasma/serum by conventional proteomic approaches is
not very feasible.
A method that has been proposed to largely overcome
these deﬁcits is isobaric labelling (iTRAQ: isobaric tags for
absolute and relative quantitation) coupled with MALDI-
TOF/TOF analysis. In this approach, the plasma peptides,
following trypsin digestion, are chemically labelled with a
discrete set of isotopes via an amine-tagging reagent [13].
These isotope tags permit ready discrimination by mass
spectrometry,therebypermittingcomparativequantiﬁcation
to a reference sample in a multiplex manner. To date, most
applications have made use of commercial 4-plex or 8-
plex reagents. By the use of these diﬀerent isobaric tags, it
is possible to examine diﬀerent samples in a single mass
spectrometric analysis.
Since this method has been shown to permit highly
reproducible comparative assessment of tagged peptides
[14], it has been suggested to be suitable for the discovery
of biomarkers in complex body ﬂuid such as plasma [15].
In a recent study we have shown that the iTRAQ isobaric
labelling approach may indeed be valid for the detection
of biomarkers for pregnancy related conditions, such as
fetuses with Down syndrome, in that we were able to discern
quantitative alterations in known screening markers such as
βhCG [16].
Conﬁdent by the validity of the iTRAQ methodology,
we have now in a pilot experiment investigated whether this
approach could be suitable for the detection of biomarkers
useful for determining pregnancies at risk for preeclampsia.
In this study we examined 12 maternal plasma samples
obtained at 12 weeks of pregnancy, of which 6 cases
subsequently developed preeclampsia, while 6 cases had
uncomplicated deliveries.
Maternal plasma peptides were examined by 4-plex
iTRAQ labelling in conjunction with a 4800 MALDI-
TOF/TOF analysis. Our results indicate that quantitative
diﬀerencescanbebeingalreadydetectedintheﬁrsttrimester
of pregnancy between pregnancies which subsequently
developedpreeclampsiaandthosewhichhadnormalhealthy
outcome.
2.MaterialsandMethods
2.1. Samples. Blood samples for this case-control proteome
study were collected prospectively from pregnant women
at approximately 12 weeks of gestation. In a retrospective
manner, 6 samples from cases that subsequently developed
preeclampsiawerematchedwith6samplesfrompregnancies
with normal healthy outcome (Table 1). This study was
undertaken with the approval of the Institutional Ethical
Board of the University Hospital, Basel, Switzerland and
written informed consent was required in all instances.
2.2. Sample Preparation. As described previously, 9mL
blood was drawn into BD P100 tubes (BD Diagnostics,
Franklin Lake, NY, USA), which are specially designed for
proteomics experiments, in that the EDTA (ethylenedi-
aminetetraacetic acid) and protease inhibitor present in the
tube prevent coagulation and stabilize the plasma proteome.
Following phlebotomy the samples were centrifuged at
3,000×gf o r3 0m i n u t e sa t1 0 ◦C, whereby the plasma was
separated from the cellular fraction by aid of a mechanical
separator, 100μLa l i q u o t sw e r es t o r e da t−80◦C until further
use. For an overview of the workﬂow used in this analysis
refer to Figure 1.
2.3. Immuno-Depletion of High-Abundance Plasma Proteins.
Highly abundant plasma proteins were depleted using
ProteoMiner protein enrichment kit (Bio-Rad Laboratories,
Inc.), as per the manufacturer’s instructions. 1mL of plasma
was used for the depletion and after the whole procedure,
300μL was eluted in elution reagent. After depletion protein
concentration was measured using RC DC Protein assay kit
(Bio-Rad Laboratories, Inc.).
2.4. Tryptic Digestion and iTRAQ Reagent Labelling. Equal
amounts (100μg) of depleted plasma protein from sixJournal of Biomedicine and Biotechnology 3
Table 1: Characteristic of study population.
(a) Criteria used for pregnancy with or without preeclampsia for the
longitudinal study
Control PE
Maternal age (years) 35.1 ±1.33 5 .1 ±6.8
Gestational age (weeks) 38.8 ±0.83 4 .9 ±2.4
Systolic BP (mmHg) 122.5 ±14.2 188.8 ±18.6
Diastolic BP (mmHg) 73.6 ±7.0 111.8 ±14.1
Proteinuria (dipstick) Negative positive
(b) Gestational window selected for the current study (n = 6) who
subsequently developed the preeclampsia
Control PE
Gestational age (years) 12.4 ±1.21 2 .3 ±1.1
Human plasma
Depletion
Reduced, cysteine block and trypsin digestion
LC MS/MS for protein identiﬁcation and quantitation 
iTRAQ labelling
Combined labelled sample
Strong cation exchange chromatography
Control: iTRAQ reagent (114)
Control: iTRAQ reagent (116)
PE: iTRAQ reagent (115)
PE: iTRAQ reagent (117)
Figure 1: Workﬂow for quantitative proteomics using iTRAQ
reagent. Equal amounts of plasma protein (100μg) from control
and PE (n = 6) were pooled separately and duplicated (technical
replicates), controls were labeled with 114 and 116 iTRAQ label,
and PE were labeled with 115 and 117 iTRAQ label. The labeled
samples were pooled and were subjected to a strong cation
exchange chromatography to remove the excess label. Afterwards,
LC-MALDI MS/MS was performed for protein identiﬁcation and
quantiﬁcation.
of the PE cases and controls were pooled separately and
splitted into two technical replicate for the iTRAQ labelling.
These samples were denatured with 2% SPE in 500mM
triethylammoniumbicarbonate(TEAB)(Sigma-Aldrich)for
15 minutes at room temperature, following which they were
reduced with 2μLof50mMtris-(2-carboxyethyl) phosphine
(TCEP) (Sigma-Aldrich) at 60◦C for 1h and were then alky-
lated with 10mM s-methyl methanethiosulfonate (MMTS)
for 10 minutes in room temperature. After alkylation, the
proteins were digested overnight at 37◦Cwi t h1U / μL trypsin
(TPCK treated) (Applied Biosystems, Foster City, CA 94404,
USA).PeptideswerelabelledwithoneunitofiTRAQReagent
Multiplex kit (Applied Biosystems, Foster City, CA 94404,
USA) that was reconstituted in 70μL of ethanol. iTRAQ
labels 114 and 116 were used separately for labelling the
pooled duplicated control sample (technical replicates), and
115 and 117 were used separately to label the pooled
duplicate preeclampsia samples (technical replicates). The
iTRAQ labelling reagent solution was added to the digest
and incubated for 1h at room temperature. To assess the
accuracy of the ratiometric quantitation of iTRAQ reagent
a split in signal was performed, and the data was corrected as
described in detail by Unwin and colleagues [17].
2.5. Strong Cation Exchange Chromatography (SCX). Strong
cation exchange chromatography was preformed to remove
the excess iTRAQ reagent and interfering substances for the
mass analysis. Dried peptides were resuspended in 200mL
of Buﬀer A and were loaded on polysulfoethyl A column
(200mm length × 4.6 id, 5μm particle size, and 200 ´ ˚ Ap o r e
size) on a BioLC HPLC unit (Dionex). Buﬀer A consisted of
10mM KHPO4, 25% acetonitrile, and 500mM KCl, pH 3.0,
and Buﬀer B consisted of 10mM KH2PO4, 25% acetonitrile,
and 500mM KCl, pH 3.0. The 60min gradient comprised
100% Buﬀer A for 5min, 5–30% Buﬀer B for 40min, 30–
100%BuﬀerBfor5min,100%BuﬀerBfor5min,andﬁnally
100% Buﬀer A for 5min. Thirteen fractions were collected
using a Foxy Jr. Fraction Collector (Dionex). Subsequently, 2
and 3 fractions were pooled according to the chromatogram
proﬁle based on the peak intensity, and all the products were
dried in a vacuum concentrator, after which they were stored
at −20◦C prior to mass spectrometric analysis.
2.6. Nano-LC-MALDI. Should we changeThe dried SCX
iTRAQ-labeled peptides were dissolved in Buﬀer A which
consists of 95% H2O, 5% acetonitrile, 0.1% TFA and were
l o a d e do nC 1 8t r a pc o l u m n( 1m m× 300μmi . d .c o l u m n )
at 30μl/minand separated on an analytical column (150mm
× 100μm i.d. column) at 500nL/min using the LC Packings
Ultimatesystem.Thepeptideswereseparatedusingalinearly
increasing concentration of acetonitrile in Buﬀer B from
5% to 30% in 120min, and from 30% to 60% in 40min.
The elute was mixed with matrix (2mg/mL alpha-cyano-
4-hydroxycinnamic acid in 80% acetonitrile, 0.1% TFA)
at a ﬂow rate of 800nl/min and deposited on an Opti-
TOF LC/MALDI (Applied Biosystems) plate in 10s fractions,
using an automatic robot, (Probot, Dionex).
2.7. MS and MS/MS. The mass spectrometer 4800 Plus
MALDI TOF/TOF Analyzer (Applied Biosystems) was set
to perform data acquisition in positive ion mode. An MS
condition of 1000 shots per spectrum was used. Monoiso-
topic precursor selection for MS/MS was done by automatic
precursor selection using an interpretation method using
the 12 most intense peaks per spot with an MS/MS mode
condition of 4000 laser shots per spectrum. Minimum peak
width was one fraction, and mass tolerance was 80ppm.
Adduct tolerance (m/z) ±0.003. MSMS was done with a gas
pressure of 2 × 10
−2 bar in the collision cell. Air was used as
collision gas.4 Journal of Biomedicine and Biotechnology
2.7.1. Protein Identiﬁcation and Database Searches. Protein
identiﬁcation and quantiﬁcation were done by using the
ProteinPilot software v2.0 (Applied Biosystems; MPE-Sciex).
The search was performed against the human database of
UniProtKB/Swiss-Prot (version 3.52, November 2008) from
the EBI website (http://www.ebi.ac.uk./IPI/IPIhelp.html),
and concatenated target-decoy database-search strategy was
used to check the false positive rate [18].
2.8. Relative Quantitation Criteria. The Paragon algorithm
[19, 20] in ProteinPilot v2.0 software was used as the default
search program with digestion enzyme set as trypsin and
methyl methanethiosulfonate as cysteine modiﬁcation. The
search also included the possibility of more than eighty
biologicalmodiﬁcationsandaminoacidsubstitutionofupto
two substitutions per peptide using the BLOSUM62 matrix.
Data was normalized for loading error by bias correction
calculated with ProGroup algorithm, and identiﬁed proteins
with at least 95% conﬁdence and with a ProtScore of
1.3 were reported. The results obtained from ProteinPilot
v2.0 software were exported to Microsoft Excel for further
analysis. The study was performed in double duplex manner,
where PE samples were labelled with 115 and 117; control
was labelled with 114 and 116. Peptides were selected based
on the criteria deﬁned in the Protein Pilot software, which
means that all the peptides were included for quantitation
with an exception for those without an iTRAQ modiﬁcation
or reporter ion; an area count less than 40 and peptides with
P value less than 0.001 were excluded [21]. As described by
Gan and colleague in their study on estimation of relative
quantitative ratio from iTRAQ experiments, we also used
only peptides above or equal to 70% conﬁdence level for the
estimation of relative quantitation [22].
2.9. PANTHER Analysis. The PANTHER database was used
to elucidate the molecular function, biological process, and
signalling pathway associated with each individual protein
(http://panther.appliedbiosystems.com/). (See Supplemen-
tary Material available online at doi:10.1155/2011/305964.)
3. Results
Samples were obtained from 6 cases which subsequently
developed preeclampsia and 6 cases which delivered normal
healthy babies. Care was taken to match both maternal and
gestational age, to rule out any confounding inﬂuence of
these two parameters.
Low-abundant-plasma proteins were enriched by using
ProteoMiner protein enrichment kit. This was accomplished
through the use of a large highly diverse bead-based library
of combinatorial peptide ligands. When plasma was applied
to the beads, a small fraction of the high-abundance
proteins saturated their high-aﬃnity ligands, and the excess
high-abundance proteins were washed away. In addition a
very small amount of high-abundance proteins and low-
abundance proteins were concentrated on their speciﬁc
aﬃnity ligands. This provides for a signiﬁcant enrichment of
medium- and low-abundant plasma proteins.
The samples were pooled separately and duplicated in
order to have more precise analytical replicate measure-
ments. The iTRAQ analysis was done in double duplex style,
the PE samples were labelled with iTRAQ 115 and 117 and
the control samples with iTRAQ 114 and 116, using the
workﬂow illustrated in Figure 1.
Following tandem MSMS, and by focussing on iTRAQ
reporter ions in low molecular mass range (114–117Da)
for quantiﬁcation, we identiﬁed 64 proteins with ≥95%
conﬁdence. However, after manually rechecking the MS/MS
data thoroughly peak by peak, only 57 out of 64 proteins
(92%)hadarelativequantitationderivedfromtheanalysisof
two or more peptides, while for 5 proteins, the quantitation
was based on single peptide. For 2 proteins no quantitation
could be ascertained by analysis using ProteinPilot. Figure 2
shows the MSMS spectrum of the precursor ([M+H]+, m/z
1259.67Da). In low-mass region the reporter ions are seen,
while the area under the curve was used for quantiﬁcation. A
concatenated target-decoy database search strategy was used
to check the false positive rate in our case, it was found to be
0%, which boosted the reliability of our data.
As we did the experiment in double duplex manner PE
(115 and 117) and control (114 and 116), it was possible
to estimate the cutoﬀ point for the diﬀerentially expressed
protein in our sample. Based on 64 relatively abundant
protein ratios from PE and control an average variation of
4.4% was (±0.04) measured. If the cutoﬀ was set at 10%
average variance then only 74% of the proteins would fall
within this variation range, butwhenit was increased to 20%
then about 98% of the proteins fall in this variation range.
So the cutoﬀ point in this experiment was set at 20%
(±0.2). That means that any relative change in protein ratio
below or above ±1.2-fold was considered as diﬀerentially
under or overexpressed Figure 3.
Thefunctionaldistributionoftheseproteinsisillustrated
in Figure 4. For this interpretation, an analysis of 64 proteins
was performed using the PANTHER classiﬁcation system,
which sorts the proteins into respective classes based on their
biological process.
It is of interest that three of the major groups involve
cell adhesion molecules (13%), extracellular matrix proteins
(13%),andmemberoftheproteasefamily(13%),andfactors
that are known to be aberrant in placental insuﬃciency
apparent in preeclampsia. Furthermore, large groups were
found to involve signalling molecules (13%) and carrier
proteins (20%).
A list of 10 of the upregulated proteins with fold
change more than 1.2 is provided in Table 2. A PANTHER
subanalysis for pathway association of these 10 proteins
indicates that 33% are associated with blood coagulation,
33% with plasminogen activation, 17% with angiotensin II,
and 17% with integrin function shown in Figure 5.
4. Discussion
The comparative quantitative assessment of serum or
plasma proteins via iTRAQ isobaric labelling combined with
MALDI-TOF/TOF analysis has suggested to be suitable forJournal of Biomedicine and Biotechnology 5
9 273.4 537.8 802.2 1066.6 1331
1 
0
10
20
30
40
50
60
70
80
90
100
I
n
t
e
n
s
i
t
y
 
(
%
)
288.225
115.1384
694.4105 972.4406
70.1012
566.3431 677.4144
175.1504
86.1286
72.1073 580.3619 243.2006
386.2328 554.3627 663.4080 1115.4928 970.4258 195.1388 310.1772 748.4077 457.3086 874.47 84.1139
145.1371
59.0911
Mass (m/z)
112.64923 113.82372 114.99821 116.17269 117.34718 118.52167
6350.2
0
10
20
30
40
50
60
70
80
90
100 115.1384 117.1453
116.1414
114.1405
113.1263
I
n
t
e
n
s
i
t
y
 
(
%
)
Mass (m/z)
(i)
(ii)
Figure 2: Components of the spectrum illustrated are (i) MS and MS spectrum of the precursor ([M+H]+, m/z 1259.67Da) (ii) low-mass
region showing the reporter ions used for quantitation. The peptide is labeled by isobaric tags at both the N-terminus and C-terminal lysine
side chain. The precursor ion and all the fragment ions therefore contain all four members of the tag set, but remain isobaric. The MS and
MS spectrum was obtained from the singly charged [M+ H]+ peptide using a 4800 MALDI TOF-TOF Analyzer.
Table 2: List of protein up regulated in iTRAQ experiment with relative protein ratio (P value 0.001).
N Acc. no. Protein names Biological processes Molecular function
1 P02679 Fibrinogen Fragment D Signal transduction Calcium ion binding
2 P10909 Clusterin isoform 2 Compliment activation Misfolded protein binding
3 P02647 Apolipoprotein A-I Signal transduction Receptor binding
4 P02751 Fibronectin Angiogenesis Collagen binding
5 P01019 Angiotensinogen Blood vessel remodeling Receptor binding
6 P09382 Galectin 3 binding Apoptosis Galactoside binding
7 P00750 Plasminogen Proteolysis Protein binding
8 P02787 Transferrin Iron ion transporter Ferric ion binding
9 P04003 C4 beta binding Compliment activation Protein binding
10 P02790 Hemopexin Heme transporter Iron ion binding
the detection of biomarkers. This is largely due to the highly
reproducible nature of the system, which exhibits little run-
to-run variation, determined after a lengthy comparison of
pooled and individual samples of case and control, yielding
ac o e ﬃcient of variation of 11.7% [15].
In a previous proof-of-principle study, we examined
whether this approach was suitable for the detection of
screening markers that could be used to screen for preg-
nancies with a Down syndrome fetus [16]. This analysis
indicated that this approach may indeed be valid, as we
found a known screening marker, namely, βhCG (β human
chorionic gonadotropin), amongst the pool of elevated
proteins we detected.
In our current study, we have now assessed whether this
method could be suitable for the detection of biomarkers
useful for PE screening. In our analysis we identiﬁed over
10 proteins whose concentration was altered in the plasma of
pregnancies that subsequentlydeveloped PE when compared
to those with normal deliveries. Amongst this group, we
observed previously described glycoproteins [12]r e p o r t e d
to be involved in the pathogenesis of PE such as ﬁbrinogen,
galectin, transferrin, hemopexin, and clusterine. Fibrinogen6 Journal of Biomedicine and Biotechnology
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Figure 3: Frequency distribution (bars) from both PE and control
replicates across diﬀerent ranges of variation. The cumulative
percentage (lines) is deﬁned as the cumulative number of proteins
falling within the deﬁned variation range against the total number
of proteins.
Protease (13%)
Signaling
molecule (13%)
Extracellular matrix (13%)
Cell adhesion
molecule (13%)
Molecular function 
unclassiﬁed (7%)
Carrier
protein (20%)
Miscellaneous
function (7%)
Regulatory
molecule (7%)
Transporter (7%)
Figure 4: Number of plasma protein identiﬁed using iTRAQ
reagent. In total, 64proteins were identiﬁed. Shown above is the
classiﬁcation of these proteins in diﬀerent categories based on
molecular function.
Plasminogen activation (33%)
Blood coagulation (33%)
Integrin (17%)
Angiotensin II (17%)
Figure 5: PANTHER analysis for pathway. In total, 10 proteins
were identiﬁed as elevated. Shown above is the diﬀerent signaling
pathways hits by these protein.
is present in the extracellular matrix of the placenta and
plays an important role in cellular and matrix interaction.
It can also play a role in inﬂammatory response, as an
increase in level of ﬁbrinogen can lead to adhesion of
leukocytes and platelets to the endothelium [23]. Pathway
analysis has shown that 33% of proteins are associated with
blood coagulation pathway [24]. This suggests a larger-than-
expected role that ﬁbrinogen is playing in the pathogenesis
of PE and needs to be further investigated in detail.
Extracellular matrix protein ﬁbronectin was also found
to be overexpressed. Fibronectin is an important glycopro-
tein with a major role in early embryogenesis, trophoblast
invasion, and vascular remodelling [25, 26]. Fibronectin
has been suggested to be a potential predictive marker for
PE. It is also of interest that 13% of proteins we detected
are associated with integrin pathway signalling, of which
ﬁbronectin is an important component.
We also found elevation in the level of apolipoprotein
A1 which is involved in lipid metabolism. We also found
altered level ins protease inhibitor (serpin) family mem-
ber angiotensinogen and proteolytic factor like plasmin.
Complement factor C4 beta, which plays important role in
compliment activation was also observed to be elevated in
our study.
In a recent study Blumenstein and colleagues [12]h a v e
also observed an elevation in clusterin prior to onset of
preeclampsia, thereby suggesting that it may also serve as a
predictive marker. In our study we were, however, able to
detect this elevation at a much earlier time-point in gestation
in those cases that subsequently developed PE.
It is of interest that the blood pressure regulating mole-
cule angiotensinogen was also amongst the group of proteins
we observed to be increased. This important molecule has
previously reported to be elevated in manifest PE. The
presence of this important screening marker in our pool of
elevated plasma proteins suggests that the strategy we have
chosen for the identiﬁcation of new biomarkers is functional
and worthy of further pursuit [27].
That our assay is indeed capable of detecting proteins
of placental origin is illustrated by presence of galectin, a
placentally derived glycoprotein. This molecule is important
in pregnancy by playing a potential role in preventing the
attack from maternal immune system on the developing
fetus, which can be seen as foreign semiallograft [28].
That the conditions leading to PE are multifactorial is
suggested by our observation that it may also involve factors
such as apolipoprotein A-I, whose altered production might
impair cholesterol transport, thereby contributing to arterial
damage in those cases which develop PE [29].
The underlying role of inﬂammatory processes are is also
underscored by our observed elevation in complement C4
beta. Although this elevation may be largely contributed by
the mother, it may be a reﬂection upon a maternal response
to the increased release of placental debris which has been
suggested to occur in pregnancies with PE.
Our study supports the current view that the iTRAQ
approach is very useful for the detection of biomarkers,
largely due to its reproducibility and robustness. However, in
order to assess the clinical utility of these new biomarkers,Journal of Biomedicine and Biotechnology 7
we will need to further investigate them using modern
technologies such as selected reaction monitoring (SRM),
which has emerged as the method of choice for biomarkers
validation using mass spectroscopy [30, 31].
As very few speciﬁc biomarkers currently exist to assist
with the screening of pregnancy-related disorders such
preeclampsia or preterm labour, it is possible that the ap-
proach we have described in this study will be useful for the
discovery of such important clinical tools.
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